Adma Biologics reported $49.19M in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
Adma Biologics USD 49.19M 7.26M Sep/2025
Alnylam Pharmaceuticals USD -29.96M 34.85M Sep/2025
Dynavax Technologies USD 21.27M 10.41M Sep/2025
Takeda JPY 257.49B 568.56B Dec/2025